Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla.

The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing authorization for the drug to treat early symptoms of the disease like mild cognitive impairment and dementia.

The approval marks the first Alzheimer's therapy registered in Australia that targets amyloids, helping slow the cognitive and functional decline in patients with early symptoms, the company said.

The treatment, which consists of an intravenous infusion every four weeks, was approved based on positive Phase 3 trial results, the company said.

The trial data shows the earlier patients are identified, diagnosed and treated with Kisunla, the greater their response to treatment, President of Lilly International Ilya Yuffa said.

The drug now has 13 regulatory authorizations, Yuffa said.